

Highlights of the 15 month period January 2009 - March 2010

NET SALES

₹ 45bn
US\$ 1bn

OPERATING PROFIT (EBIDTA)

₹ 8.2bn
US\$ 190mn

◆ Wockhardt wins Government of India Patent Award as the 'Pharmaceutical Company with the maximum number of Patent filings and grants from India'. Total 74 patents granted

◆ Launch of Spectra division to serve extra-urban and rural markets in India

◆ Dedicated Cardiology division launched in India

◆ Launched Alyante, a custom research and manufacturing division partnering other pharma companies in their research activities

◆ Solid and sterile facility at Aurangabad and liquid facility at Morton Grove pass a full-fledged US FDA inspection

◆ 22 ANDAs approved by the US FDA and 18 approvals from the European Union

◆ Wockhardt UK wins a special tender for critical supplies to the Department of Health

◆ Wockhardt UK finalises two new manufacturing contracts for future business

◆ Wockhardt launches 51 new products globally

◆ Wockhardt's Information Technology department wins the 'CIO 100 Award' for the second consecutive year, exemplifying the highest level of operational and strategic excellence in IT

◆ Wockhardt Foundation, the CSR arm of Wockhardt, touches 43 million lives through its various medical and social programmes and initiatives.

